Cellusion is a Japanese regenerative medicine start-up from Keio University, School of Medecine in Japan.
The first pipeline CLS001 is aim to solve the global blindness issue around corneal transplanatation.
Cellusion has several unique technologies including highly efficient direct differentiation induction method to produce corneal endothelial substituted cells from iPS cells. Cellusion‘s lead program coded as CLS001 is targeting Bullous Keratopathy which is a major corneal endothelial disease currently treated only by corneal transplantation. The First-in-human investigator-initiated clinical study of CLS001 is under going in Keio university hospital. And, Cellusion is now under preparation of company sponsored clinical trials both in Japan the USA.
The first pipeline CLS001 is aim to solve the global blindness issue around corneal transplanatation.
Cellusion has several unique technologies including highly efficient direct differentiation induction method to produce corneal endothelial substituted cells from iPS cells. Cellusion‘s lead program coded as CLS001 is targeting Bullous Keratopathy which is a major corneal endothelial disease currently treated only by corneal transplantation. The First-in-human investigator-initiated clinical study of CLS001 is under going in Keio university hospital. And, Cellusion is now under preparation of company sponsored clinical trials both in Japan the USA.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Tokyo
Company HQ Country:
Japan
Year Founded:
January 2015
Main Therapeutic Focus:
Regenerative Medicine
Lead Product in Development:
CLS001
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
